Cross Country Healthcare Q1 2024 Adj EPS $0.19 Beats $0.17 Estimate, Sales $379.174M Beat $374.089M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cross Country Healthcare (CCRN) reported Q1 2024 adjusted EPS of $0.19, surpassing the $0.17 estimate, with sales of $379.174M also beating the $374.089M estimate. However, this represents a significant decrease from the previous year, with earnings down 77.38% and sales down 39.11%.
May 01, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CCRN's Q1 2024 earnings and sales exceeded estimates, but showed a significant decline from the previous year's figures.
While CCRN's earnings and sales for Q1 2024 beat analyst estimates, the substantial year-over-year decline in both earnings and sales could concern investors. The positive earnings surprise may provide short-term support to the stock price, but the significant decreases compared to the previous year highlight potential challenges in the company's performance and growth, possibly leading to mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100